Prevention of HIV infection among injection drug users in resource-limited settings

David Vlahov, Angela M. Robertson, Steffanie A. Strathdee

Research output: Contribution to journalArticle

Abstract

Injection drug use contributes to considerable global morbidity and mortality associated with human immunodeficiency virus (HIV) infection and AIDS and other infections due to blood-borne pathogens through the direct sharing of needles, syringes, and other injection equipment. Of ∼16 million injection drug users (IDUs) worldwide, an estimated 3 million are HIV infected. The prevalence of HIV infection among IDUs is high in many countries in Asia and eastern Europe and could exacerbate the HIV epidemic in sub-Saharan Africa. This review summarizes important components of a comprehensive program for prevention of HIV infection in IDUs, including unrestricted legal access to sterile syringes through needle exchange programs and enhanced pharmacy services, treatment for opioid dependence (ie, methadone and buprenorphine treatment), behavioral interventions, and identification and treatment of noninjection drug and alcohol use, which accounts for increased sexual transmission of HIV. Evidence supports the effectiveness of harm-reduction programs over punitive drug-control policies.

Original languageEnglish (US)
JournalClinical Infectious Diseases
Volume50
Issue numberSUPPL. 3
DOIs
StatePublished - May 15 2010
Externally publishedYes

Fingerprint

Virus Diseases
Drug Users
HIV
Injections
Needle Sharing
Needle-Exchange Programs
Blood-Borne Pathogens
Harm Reduction
Eastern Europe
Buprenorphine
Pharmaceutical Services
Africa South of the Sahara
Drug and Narcotic Control
Methadone
Syringes
Pharmaceutical Preparations
Opioid Analgesics
Acquired Immunodeficiency Syndrome
Therapeutics
Alcohols

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)

Cite this

Prevention of HIV infection among injection drug users in resource-limited settings. / Vlahov, David; Robertson, Angela M.; Strathdee, Steffanie A.

In: Clinical Infectious Diseases, Vol. 50, No. SUPPL. 3, 15.05.2010.

Research output: Contribution to journalArticle

Vlahov, David ; Robertson, Angela M. ; Strathdee, Steffanie A. / Prevention of HIV infection among injection drug users in resource-limited settings. In: Clinical Infectious Diseases. 2010 ; Vol. 50, No. SUPPL. 3.
@article{f5288511799d42039d6aaf985a44445e,
title = "Prevention of HIV infection among injection drug users in resource-limited settings",
abstract = "Injection drug use contributes to considerable global morbidity and mortality associated with human immunodeficiency virus (HIV) infection and AIDS and other infections due to blood-borne pathogens through the direct sharing of needles, syringes, and other injection equipment. Of ∼16 million injection drug users (IDUs) worldwide, an estimated 3 million are HIV infected. The prevalence of HIV infection among IDUs is high in many countries in Asia and eastern Europe and could exacerbate the HIV epidemic in sub-Saharan Africa. This review summarizes important components of a comprehensive program for prevention of HIV infection in IDUs, including unrestricted legal access to sterile syringes through needle exchange programs and enhanced pharmacy services, treatment for opioid dependence (ie, methadone and buprenorphine treatment), behavioral interventions, and identification and treatment of noninjection drug and alcohol use, which accounts for increased sexual transmission of HIV. Evidence supports the effectiveness of harm-reduction programs over punitive drug-control policies.",
author = "David Vlahov and Robertson, {Angela M.} and Strathdee, {Steffanie A.}",
year = "2010",
month = "5",
day = "15",
doi = "10.1086/651482",
language = "English (US)",
volume = "50",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Prevention of HIV infection among injection drug users in resource-limited settings

AU - Vlahov, David

AU - Robertson, Angela M.

AU - Strathdee, Steffanie A.

PY - 2010/5/15

Y1 - 2010/5/15

N2 - Injection drug use contributes to considerable global morbidity and mortality associated with human immunodeficiency virus (HIV) infection and AIDS and other infections due to blood-borne pathogens through the direct sharing of needles, syringes, and other injection equipment. Of ∼16 million injection drug users (IDUs) worldwide, an estimated 3 million are HIV infected. The prevalence of HIV infection among IDUs is high in many countries in Asia and eastern Europe and could exacerbate the HIV epidemic in sub-Saharan Africa. This review summarizes important components of a comprehensive program for prevention of HIV infection in IDUs, including unrestricted legal access to sterile syringes through needle exchange programs and enhanced pharmacy services, treatment for opioid dependence (ie, methadone and buprenorphine treatment), behavioral interventions, and identification and treatment of noninjection drug and alcohol use, which accounts for increased sexual transmission of HIV. Evidence supports the effectiveness of harm-reduction programs over punitive drug-control policies.

AB - Injection drug use contributes to considerable global morbidity and mortality associated with human immunodeficiency virus (HIV) infection and AIDS and other infections due to blood-borne pathogens through the direct sharing of needles, syringes, and other injection equipment. Of ∼16 million injection drug users (IDUs) worldwide, an estimated 3 million are HIV infected. The prevalence of HIV infection among IDUs is high in many countries in Asia and eastern Europe and could exacerbate the HIV epidemic in sub-Saharan Africa. This review summarizes important components of a comprehensive program for prevention of HIV infection in IDUs, including unrestricted legal access to sterile syringes through needle exchange programs and enhanced pharmacy services, treatment for opioid dependence (ie, methadone and buprenorphine treatment), behavioral interventions, and identification and treatment of noninjection drug and alcohol use, which accounts for increased sexual transmission of HIV. Evidence supports the effectiveness of harm-reduction programs over punitive drug-control policies.

UR - http://www.scopus.com/inward/record.url?scp=77951868127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951868127&partnerID=8YFLogxK

U2 - 10.1086/651482

DO - 10.1086/651482

M3 - Article

C2 - 20397939

AN - SCOPUS:77951868127

VL - 50

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - SUPPL. 3

ER -